Trial Profile
A Multicentre, Two Stage, Randomised, Double Blind Study of the Safety, Tolerability and Immunogenicity of a Human Immunodeficiency Virus (HIV) Vaccine Candidate, HIV-v.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV vaccine (Primary) ; Montanide ISA-51
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors SEEK
- 08 Oct 2013 Phase Ib results published in Vaccine.
- 18 Jul 2011 Results will be presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, according to a SEEK media release.
- 14 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.